The Big Road Ahead for Nanoparticles and Radiation Therapy
Nanobiotix is a late clinical-stage nanomedicine company pioneering new approaches in cancer. NBTXR3 is a first-in-class product which when activated by radiation therapy, physically destroys cancer cells and activates the immune system for both local control and systemic disease treatment. Currently, the company is evaluating NBTXR3 in seven clinical trials with a focus on head and neck cancers and Immuno-Oncology programs. Please join us on Monday, October 22nd at 3:45pm as our CEO Dr. Laurent Levy discusses “The Big Road Ahead for Nanoparticles and Radiation Therapy.”
Contact: Monica Sukhatme
The asset you are trying to access is locked. Please enter your access key to unlock.